Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 4
Abstract
Background and rationale for the study. We assessed the association of CD4+ T-cell counts and HIV-RNA on sustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coinfected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between 2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results. We studied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reduced odds of SVR included genotype 1 or 4, HCV-RNA > 500,000 IU/mL, advanced liver fibrosis, CDC clinical category C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparison with patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio [95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57) for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclusions. Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However, this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this represents a true association of HIV-RNA on response to PR or a spurious association due to poor adherence to treatment.
Authors and Affiliations
Teresa Aldámiz-Echevarría, Juan González-García, Miguel A. Von Wichmann, Manel Crespo, José López-Aldeguer, Carmen Quereda, María J. Téllez, María J. Galindo, Ignacio Santos, Josep M. Guardiola, José M. Bellón, Marisa Montes, Juan Berenguer
Keywords
Related Articles
- EP ID EP78471
- DOI -
- Views 116
- Downloads 0
Thoracic empyema due to migrated gallstones
Hepatobiliary conditions should be considered in the differential diagnosis of right pleural effusion. Here we present the illustrative images of thoracic empyema due to migrated gallstones in a woman who was treated for...
Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
[b]Background[/b]. Probiotics have profound effect on nonalcoholic steatohepatitis (NASH) in animal models. We aimed to test the hypothesis that probiotics treatment was superior to usual care in reducing liver fat in NA...
Adenovirus hepatitis presenting as tumoral lesions in an immunocompromised patient
A 59-year-old man with T-cell prolymphocytic leukemia on alemtuzumab presented with neutropenic fever, intermittent nausea, and multiple ill-defined low attenuation foci in the liver on abdominal computed tomography scan...
Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferonplus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes...
Promotor methylation: Does it affect response to therapy in chronic Hepatitis C (G4) or fibrosis?
Background and aim. DNA methylation plays a critical role in the control of important cellular processes. The present study assessed the impact of promoter methylation (PM) of some genes on the antiviral response to anti...